Lead by proven industry experience, Marvel is at the forefront of modern science.

We are a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug. Our business model capitalizes on significantly lower cost, less time and a lower risk profile to bring a drug asset to commercialization faster than the traditional long-term biotech model.

The Company has been specifically focused on the discovery of new chemical entities that inhibits the A2a adenosine receptor. The A2a receptor is a target for a number of diseases representing areas of significant unmet medical needs, each with multi-billion dollar potential, and with fundamentally no competitors.

Our drug assets are targeted for the treatment of large and growing markets associated with a predominantly aging population.

 

The Company is targeting specifically

Neurological Diseases
that have not been treated with
conventional therapeutics

Non-Alcoholic
Steatohepatitis (NASH)
Currently no approved therapies

Cancer
Pursuing as an adjunctive
therapy

Stock Information

 

Shares Outstanding : 39,786,231
Insider Ownership : 13,575,098 (34.1%)
Stock options granted : 3,350,000

Corporate Factsheet

Marvel Factsheet Download

 

 

 

 

Recent News

Marvel Biosciences Closes Private Placement

Calgary, Alberta, Canada, July 19, 2024 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to report that, further to its press releases of May 16, 2024 and June 21,...

Contact

Marvel Biosciences Corp.
Suite 420, 505 8th Avenue S.W.
Calgary, Alberta T2P 1G2

(403) 770-2469

 

Marvel Biosciences

Marvel Biosciences Corp. (the “Company”) is a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug.

Email Us

11 + 14 =